Mostrar el registro sencillo del ítem
Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study
dc.contributor.author | Antolin, A. Rodriguez | |
dc.contributor.author | Martinez-Pineiro, L. | |
dc.contributor.author | Romero, M. E. Jimenez | |
dc.contributor.author | Ramos, J. B. Garcia | |
dc.contributor.author | López Bellido, Dionisio | |
dc.contributor.author | del Toro, J. Munoz | |
dc.contributor.author | Garcia-Porrero, A. Garcia | |
dc.contributor.author | Veiga, F. Gomez | |
dc.date.accessioned | 2022-02-02T08:15:47Z | |
dc.date.available | 2022-02-02T08:15:47Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1471-2490 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796370/pdf/12894_2019_Article_527.pdf | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16065 | |
dc.description.abstract | BACKGROUND: Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. METHODS: This was a cross-sectional, multicentre study. Male chemo-naive adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). RESULTS: A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 +/- 16.3 and 108.7 +/- 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone >/=3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone >/=3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). CONCLUSION: Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naive CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naive mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. TRIAL REGISTRATION: Not applicable since it is not an interventional study. | en |
dc.language.iso | eng | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Cross-Sectional Studies | * |
dc.subject.mesh | Prostatic Neoplasms | * |
dc.subject.mesh | Fatigue | * |
dc.subject.mesh | Quality of Life | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Prevalence | * |
dc.title | Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study | en |
dc.type | Artigo | es |
dc.identifier.doi | 10.1186/s12894-019-0527-8 | |
dc.identifier.pmid | 31619215 | |
dc.identifier.sophos | 34150 | |
dc.issue.number | 1 | es |
dc.journal.title | Bmc urology | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Uroloxía | es |
dc.page.initial | 92 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.decs | anciano | * |
dc.subject.decs | neoplasias de la próstata | * |
dc.subject.decs | prevalencia | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | humanos | * |
dc.subject.decs | fatiga | * |
dc.subject.decs | estudios transversales | * |
dc.subject.decs | calidad de vida | * |
dc.subject.keyword | CHUO | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 19 | es |